

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)

Searching 1976 to present...






Results of Search in 1976 to present db for:


ABST/"natural ligand" OR ACLM/"natural ligand": 26 patents.

Hits 1 through 26 out of 26

[Jump To:](#)[Refine Search:](#)

PAT. NO.	Title
1 6,692,964	Methods for transfecting T cells
2 6,638,914	Pharmaceutical administration of adenosine agonists
3 6,566,079	Methods for analyzing protein binding events
4 6,518,480	Selective target cell activation by expression of a G protein-coupled receptor activated superiorly by synthetic ligand
5 6,485,929	Method for inhibiting CD95-independent apoptosis in AIDS
6 6,479,258	Non-stochastic generation of genetic vaccines
7 6,475,733	Cell surface receptors for the detection and identification of compounds
8 6,444,438	Method for the preparation of a protein by yeasts using an inducible system, vectors and correspondence transformed strains
9 6,352,694	Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
10 6,310,078	Substituted amino acids as erythropoietin mimetics
11 6,306,595	Design of drugs involving receptor-ligand-DNA interactions
12 6,287,874	Methods for analyzing protein binding events
13 6,262,234	Nuclear receptor polypeptide ZPPAR4
14 6,258,358	Targeted immunostimulation with bispecific reagents
15 6,248,332	Targeted immunostimulation with bispecific reagents
16 5,925,349	Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
17 5,888,741	Computer-based design and screening of molecules using DNA interactions
18 5,888,738	Design of drugs involving receptor-ligand-DNA interactions
19 5,786,454	Modified SH2 domains
20 5,766,856	Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
21 5,705,335	Design of drugs involving receptor-ligand-DNA interactions

- 22 5,695,752  Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
- 23 5,512,268  Polymeric shells for medical imaging prepared from synthetic polymers, and methods for the use thereof
- 24 5,506,210  Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs
- 25 5,434,052  Complementation assay for drug screening
- 26 5,393,737  Cytotoxic drug conjugates for treatment of neoplastic diseases
-



AMENDMENT

A listing of the claims presented in this patent application appears below. This listing replaces all prior versions and listing of claims in this patent application.

Claim 1 (currently amended): A method of identifying a compound which modulates binding of a natural ligand to the EGF receptor, ErbB3 or ErbB4, or which modulates signal transduction ~~via~~ by binding to the EGF receptor, ErbB2, ErbB3 or ErbB4, which method comprises the steps of:

(A) assessing the stereochemical complementarity between the compound and ~~the~~ a molecule, wherein the molecule comprises:

(i) amino acids 1-621 of the EGF receptor positioned at atomic coordinates ~~substantially~~ as shown in Figure 6;

(ii) one or more subsets of said amino acids related to the coordinates shown in Figure 6 by whole body translations and/or rotations; or

(iii) amino acids present in the amino acid sequence of ErbB2, ErbB3 or ErbB4, which form an equivalent three-dimensional structure to that of the receptor site defined by amino acids 1-621 of the EGF receptor positioned at atomic coordinates ~~substantially~~ as shown in Figure 6;

(B) ~~obtaining~~ selecting a compound assessed in step (A) which possesses stereochemical complementarity to the molecule; [and]

(C) testing the compound in vivo or in vitro for its ability to

(i) modulate binding of a natural ligand to the EGF receptor, ErbB3 or ErbB4, or

(ii) modulate signal transduction ~~via~~ by binding to the EGF receptor, ErbB2, ErbB3 or ErbB4[.]; and

(D) selecting a compound tested in step (C) that has the ability to

(i) modulate binding of a natural ligand to the EGF receptor, ErbB3 or ErbB4, or

(ii) modulate signal transduction by binding to the EGF receptor, ErbB2, ErbB3 or ErbB4.

Fast Prediction and Visualization of Protein Binding Pockets with PASS

G. Patrick Brady, Jr.¹ and Pieter F.W. Stouten¹

DuPont Pharmaceuticals Company

¹Experimental Station E500
Route 141 & Henry Clay Road
Wilmington, DE 19880-0500
G.Patrick.Brady@dupontpharma.com
Phone: (302)-695-3834
Fax: (302)-695-2209

¹Present address:

Pharmacia & Upjohn
Viale Pasteur 10
20014 Nerviano (Mi)
Italy

Summary

PASS (Putative Active Sites with Spheres) is a simple computational tool that uses geometry to characterize regions of buried volume in proteins and to identify positions likely to represent binding sites based upon the size, shape, and burial extent of these volumes. PASS'S utility as a predictive tool for binding site identification is tested by predicting known binding sites of proteins in the PDB using both complexed macromolecules and their corresponding apo-protein structures. The results indicate that PASS can serve as a front-end to fast docking. The main utility of PASS lies in the fact that it can analyze a moderate-size protein (~ 30 kD) in under twenty seconds, which makes it suitable for interactive molecular modeling, protein database analysis, and aggressive virtual screening efforts. As a modeling tool, PASS (i) rapidly identifies favorable regions of the protein surface, (ii) simplifies visualization of residues modulating binding in these regions, and (iii) provides a means of directly visualizing buried volume, which is often inferred indirectly from curvature in a surface representation. PASS produces output in the form of standard PDB files, which are suitable for any modeling package, and provides script files to simplify visualization in Cerius2®, InsightII®, MOE®, Quanta®, RasMol®, and Sybyl®. PASS is freely available to all.

Keywords: protein active site, binding site, cavity detection, buried volume, molecular modeling, computer-aided drug design



Introduction


The identification and visualization of protein cavities is the starting point for many structure-based drug design (SBDD) applications. Sites of activity in proteins usually lie in cavities, where the binding of a substrate typically serves as a mechanism for triggering some event, such as a chemical modification or conformational change. Consequently, binding sites are often targeted in attempts to interrupt molecular processes via therapeutics. Although binding site locations are often furnished by x-ray data or fold recognition, tools that automatically predict these locations have become quite popular in SBDD, especially as front-ends to molecular docking or when alternate binding sites are sought [1, 2]. The size and shape of protein cavities dictates the three-dimensional geometry of ligands that can strongly bind there; i.e. they must fit like a hand in glove. Thus, a minimal requirement for drug activity is that the molecule sterically fit the region of buried volume inscribing the active site cavity, with some allowance for induced fit. The determination and visualization of these volumes is critical in drug design, particularly since manual intervention is still fruitfully employed in most design scenarios. An ordinary stick representation of a protein, unfortunately, provides little insight regarding the location, shape, or size of its buried volumes. While surface representations [3, 4] are a step in the right direction, they still fall short in that they require the user to infer buried volumes from often-occluded void space. Consequently, methods for direct display of regions of buried volume in proteins have

become prevalent in recent years [5-11]. Moreover, as molecular docking and virtual screening become more predictive and prevalent, the possibility of interfacing such tools with functional genomics via threading or homology modeling becomes increasingly tempting. A versatile tool that can rapidly predict binding sites should, therefore, find a niche as a front-end to such automated screening efforts. This paper describes a program called PASS (Putative Active Sites with Spheres), which may serve both as an interface to virtual screening and as a visualization aid for manual molecular modeling.

Methods

The PASS algorithm is designed to fill the cavities in a protein structure with a set of spheres and to identify a few of these spheres (called “active site points”, ASPs) that most likely represent the centers of binding pockets. Crevice filling is performed in layers using three-point Connolly-like [3] sphere geometry. An initial coating of probe spheres is calculated with the protein as substrate, then additional layers of probes are accreted onto the previously found probe spheres. Only probes with low solvent exposure are retained, and the routine finishes when an accretion layer produces no new buried probe spheres. Although physical arguments can be made to substantiate PASS’S success in binding site prediction, the algorithm itself is purely geometrical (see Figure 1).

Figure 1 - PASS Algorithm



Active Site Points (ASPs)

a. PASS uses three-point geometry to coat the protein with an initial layer of spherical probes. b. These probes are filtered to eliminate those that (i) clash with the protein, (ii) are not sufficiently buried, and (iii) lie within 1Å of a more buried probe. c. A new layer of spheres (white) is accreted onto a scaffold consisting of all previously-identified probes (shaded). d. The probes are filtered as described in step b. e. Accrete a new layer of spheres onto the existing probes, as in step c. f. Accretion and filtering (steps e and d) are repeated until a layer is encountered in which no newly-found probes survive the filters. This leaves the final set of probe spheres. g. Probe weights (PW) are computed for each sphere and active site points (ASPs) are identified from amongst the final probes. h. The final PASS visualization is produced. By default, the final probe spheres are first smoothed, leaving only clusters of four or more.

Final Probes

Calculation of Probe Spheres

PASS begins by reading the Protein Data Bank (PDB) coordinates of a target protein and assigning elemental atomic radii (Table 1). Since a protein with explicitly represented hydrogen atoms contains less interstitial volume than one without hydrogen, PASS assigns a few different parameter values in the two cases. By default, if less than 20% of the atoms in the protein PDB file are hydrogen, then all hydrogen atoms are removed and hydrogen-free parameters are assigned; otherwise, hydrogen is retained and hydrogen-inclusive parameters are assigned (Table 1). The first layer of probe spheres is computed by looping over all unique triplets of protein atoms and, if they are close enough together, calculating the two locations at which a probe sphere (of radius R_{probe}) may lie tangential to all three protein atoms (Fig. 1; Step a). Appendix A elucidates this three-point geometry, which is nontrivial since the radii are not necessarily equal. To be retained, a putative probe sphere must survive several filters (Fig. 1; Step b). The first condition is that it cannot overlap with any atoms of the accretion substrate. The second filter explicitly prohibits the probe from clashing with any protein atoms, while the third ensures that the probe be somewhat buried within the protein (i.e. in a binding-site-like region). In particular, each probe sphere is ascribed a “burial count” (BC) representing the extent to which it is excluded from solvent (Figure 2). The BC of a probe is computed by counting the number of protein atoms that lie within a radius $R_{\text{BC}}=8\text{\AA}$ of it, and the probes are filtered such that any probe sphere with BC less than a threshold value ($\text{BC}_{\text{threshold}}$) is rejected. This threshold value was determined empirically, as were many of the PASS parameters, by visual inspection of


results for a few test systems. Our experience has been that PASS'S predictions are largely insensitive to the precise values of any of its parameters. Finally, probe spheres are "weeded" such that no two probe centers lie any closer together than $R_{\text{weed}} = 1\text{\AA}$. This keeps the distribution of probe spheres from becoming clumped, which enables reliable prediction of active site points from the final set of probes.

Table 1 - PASS Parameters

Parameter	
R_{probe} hydrogen-free	1.8 Å
$BC_{\text{threshold}}$ hydrogen-free	55
R_{probe} with hydrogen	1.5 Å
$BC_{\text{threshold}}$ with hydrogen	75
R_{BC}	8.0 Å
R_{weed}	1.0 Å
$R_{\text{accretion}}$	0.7 Å
R_o	2.0 Å
D_o	1.0 Å
R_{ASP}	8.0 Å
PW_{min}	1100
Elemental Radii [40]	
Hydrogen	1.20 Å
Oxygen	1.52 Å
Nitrogen	1.55 Å
Carbon	1.70 Å
Sulfur	1.80 Å

Values of PASS parameters, which are defined as follows. R_{probe} - Radius of a probe sphere. $BC_{\text{threshold}}$ - Threshold burial count (BC) distinguishing a buried probe from an exposed one. R_{BC} - Radius used to compute burial counts. R_{weed} - Minimal separation between probe spheres. $R_{\text{accretion}}$ - Radius of probes as they are accreted onto existing probes. R_o , D_o - Parameters defining the probe weight (PW) envelope function (see Fig. 2). R_{ASP} - Minimal distance between active site points (ASPs). PW_{min} - Minimal PW for an ASP.

Figure 2 - Burial Counts and Probe Weights



The burial count (BC) of a probe sphere is obtained by counting the number of protein atoms that lie within $R_{BC} = 8\text{\AA}$ of it. The probe weight (PW) of a sphere is obtained by summing the BCs of neighboring probe spheres, scaled by the distance-dependent envelope function shown above. $R_o = 2.0\text{\AA}$ and $D_o = 1.0\text{\AA}$.

After the seminal layer of probes is computed, additional layers of spheres are iteratively accreted onto the existing probe spheres. At each iteration, a set of new probe spheres is computed as described above (Fig. 1; Steps c,e), but with a smaller probe radius ($R_{\text{accretion}} = 0.7\text{\AA}$) and with the set of all probe spheres retained from previous layers as the accretion substrate. New probes, however, must still maintain a center-to-center distance of at least $R_{\text{probe}} + \sigma_i$ from each protein atom, i (of radius σ_i). The aforementioned filters are imposed when the newly-found spheres are combined with those retained from previous layers (Fig. 1; Step d). PASS continues the accretion phase until a layer is encountered in which none of the newly-found probe spheres survives the filters (Fig. 1; Step f). The result of this procedure is that the cavities, invaginations, and internal voids in the protein are filled with a set of fairly evenly-spaced probe spheres, all of which are buried and none of which sterically clashes with the protein. Furthermore, probes lying along the protein surface are packed in ideal steric contact with three protein atoms.

Active Site Point (ASP) Determination

PASS subsequently identifies a small number of “active site points” (ASP) from amongst the final set of probe spheres (Fig. 1; Step g). These ASPs are meant to represent potential binding sites (i.e. centers of putative active sites) for ligands of arbitrary shape and polar character. Thus, PASS conservatively views a protein binding site as simply an invagination in the protein surface that is large enough to accommodate a ligand and possesses substantial solvent-excluded volume in which

hydrophobic ligand moieties may be buried. ASPs are accordingly selected by identifying the central probes in regions that contain many spheres with high BCs. In particular, each probe is assigned a “probe weight” (PW), which is proportional to the number of probe spheres in the vicinity and the extent to which they are buried. The probe weight of the i^{th} probe is given by $PW(i) \equiv \sum_{j=1}^{N_{\text{probes}}} BC(j) f(|\mathbf{r}_i - \mathbf{r}_j|)$, where the envelope function, $f(r)$, is shown in Figure 2. This is conceptually similar to the solvation term of Stouten et al. [12], the premise of which is that the solvation energy of an atom varies linearly with its exposure which, in turn, is proportional to the unoccupied volume around it. The final ASPs are determined by cycling through the probes in descending order of PW, keeping only those with $PW \geq PW_{\text{min}}$ ($=1100$) that are separated by a minimum distance R_{ASP} ($= 8\text{\AA}$) from the ASPs already identified. Finally, the set of ASPs is rank-ordered according to PW values. These are PASS'S predicted binding sites.

PASS Output

The default PASS output consists of (i) a PDB file containing the final set of probe spheres, (ii) a PDB file of the ASPs, and (iii) a separate PDB file for each ligand that was optionally read in (see below). By default, PASS “smoothes” the probe spheres before writing the final set of “display” probes to a PDB file. In particular, only probes with at least 4 display probes lying within 2.5\AA are written to file by default. Smoothing removes all but appreciable groupings of probe spheres, leaving the final

visualization less cluttered. Smoothing can be suppressed via the command-line flag [-all]. PASS also produces visualization scripts for several popular molecular modeling packages; namely, Cerius2[®][13], InsightII[®][14], MOE[®][15], Quanta[®][16], RasMol[®][17], and Sybyl[®][18]. These scripts, which are optionally produced via command-line flags (e.g. [-InsightII]), simplify visualization by automatically loading, rendering, and coloring the protein, probe spheres, ASPs, and ligands. PASS also displays detailed runtime information, including parameter settings, an account of sphere calculation and filtering (e.g. Table 2), and final probe sphere and ASP data, including BCs and PWs. PASS can also read the coordinates of bound ligands, either automatically from the protein PDB file (as HETATM entries with different residue names), or as separate files via the command-line flag [-ligand <filename.pdb>]. For each ligand, PASS computes the distance from each ASP to the nearest ligand atom and to the ligand center of mass. Other command-line options enable the user to (i) produce an enhanced set of probe spheres and ASPs ([-more]), (ii) repress production of the probe sphere PDB file ([-noprobes]), (iii) treat water molecules as part of the protein ([-water]), rather than ignoring them (which is the default behavior), (iv) specify an explicit output path ([-outdir <directory_path>]), (v) produce a set of PDB files containing subsets of the final probe spheres that were produced in the various layers of sphere calculation ([-layers]), and (vi) compute the volumes of all groupings of probe spheres left after smoothing ([-volume]). None of these options slows PASS noticeably except the volume calculation, which proceeds as follows. After probe smoothing, the final set of display probes is agglomeratively clustered [19] by iteratively merging pairs of overlapping groups of probes until an iteration attempts to join two non-overlapping clusters. This determines

both the optimal number of probe groups and the identities of spheres in these groups. Group volumes are subsequently computed by looping over probe spheres and estimating the volume increments statistically. If ligand(s) are present, distances are computed from the center of each group (i.e. the cluster center) to (i) the nearest ligand atom (D_{near}), and (ii) the ligand center of mass (D_{COM}).

Results

Table 2 shows the numbers of probe spheres retained at various stages of a PASS calculation on thermolysin (1hyt) and is meant to provide an impression of the practical operation of the algorithm. In layer #1 of the probe sphere calculation, the protein atoms constitute the accretion substrate, and every set of three protein atoms lying close enough together to be simultaneously touched by a single sphere (of radius R_{probe}) must be identified and used to determine two putative probe sphere positions. The number of atomic triples that must be tried is reduced by first identifying atomic neighborhoods. The “neighborhood” of atom “i” is the set of atoms lying close enough to “i” to be bridged by a single probe sphere. In layer #1, 769,205 triples of protein atoms satisfied the neighborhood criterion, and 1,154,010 “bridging spheres” were located using these triplets. The number of bridging spheres is less than twice the number of atomic triples because not all triples of atoms in the accretion substrate that satisfy the neighborhood criterion can actually be bridged by a sphere of radius R_{probe} . The set of bridging spheres is then filtered according to (i) clash with the accretion

Table 2 - PASS Probe Sphere Algorithm Applied to Thermolysin (1hyt)

	Layer #1	Layer #2	Layer #3	Layer #4	Layer #5	Layer #6	Layer #7
Accretion Substrate	Protein	Probes	Probes	Probes	Probes	Probes	Probes
Triplets of Substrate Spheres Tried	769,205	384	1,320	2,138	1,852	1,067	1,194
Bridging Spheres Found	1,154,010	560	2,120	3,386	2,954	1,690	1,898
... after substrate clash filter	2,151	306	430	370	222	104	108
... after protein clash filter	2,151	118	115	88	53	16	14
... after burial filter	811	98	64	32	12	7	0
... after weeding filter (New Probes)	360	60	41	21	7	3	0
Total Probe Spheres	360	420	461	482	489	492	492
Comment	Seminal Protein Coat	Accretion	Accretion	Accretion	Accretion	Accretion	Completion

The numbers of spheres retained at various stages of a PASS calculation on thermolysin (1hyt). Protein atoms form the substrate in the first layer; previously identified probe spheres form the substrate in all subsequent layers. A triplet of substrate spheres is tried if each substrate pair can be bridged by a probe sphere. There are two possible probe sphere positions for each valid triplet of substrate spheres. The number of bridging spheres found is always less than twice the number of triplets tried because of exceptional cases (e.g. one sphere lying inside the other two). The bridging spheres are then subjected to a series of filters. The number of probes surviving the filters are shown. Accretion proceeds until a layer produces no new probes, which occurs in the seventh layer in this case.

substrate, (ii) clash with the protein, (iii) burial count, and (iv) proximity to other probe spheres, in that order. After the substrate clash filter, 2,151 putative probe spheres remain and, since the protein is the accretion substrate in layer #1, the same number remains after the protein clash filter. All but 811 putative probes are discarded based upon insufficient burial, and 360 remain after these 811 are “weeded” to maintain a mutual separation of at most $R_{\text{weed}}=1.0 \text{ \AA}$. Thus, 360 probe spheres are found in the first layer. The accretion substrate for the second and subsequent “accretion” layers is the set of probe spheres. In layer #2, the substrate of 360 probe spheres requires that 384 substrate triples be tested, from which 560 bridging spheres are identified. After applying the four filters, only 60 new probe spheres remain, bringing the total number of probes to 420 after layer #2. This process is repeated until layer #7, in which no new probe spheres are identified, signalling the completion of probe sphere determination. Note that although the number of probe spheres continually grows as accretion proceeds, the number of accretion substrate triples that must be tried in each layer plateaus. This is because PASS is written such that only triples of substrate atoms incorporating a newly-found probe sphere (or the neighbor of a freshly-weeded probe) are tried. As a result, PASS’S performance scales favorably with protein size (approximately $\text{MW}^{3/2}$ over the molecular weight range in Table 3).

PASS was first tested for its ability to identify known binding sites. Table 3 shows the results of applying PASS to 30 protein-ligand complexes drawn from the PDB. The structures were chosen based upon diversity, resolution, inclusion in previous theoretical studies, and the existence of corresponding apo-protein x-ray structures in the PDB. In each case, hydrogen-free PASS parameters were assigned

Table 3 - PASS Results for PDB Complexed Proteins^a

PDB Code	Protein	Ligand(s) ^b	Size (kD)	Layers	Probes	ASPs ^c	Binding Site Hits ^d	D _{near} (Å) ^e	D _{com} (Å) ^f	CPU Time (sec) ^g
1abe	l-arabinose binding protein	l-arabinose	31	8	468	4	3	1.1	0.5	12
1bid	thymidylate synthase	DUMP	28	10	572	4	1	3.0	6.3	10
1cdo	alcohol dehydrogenase ^h	NAD	37	8	760	7	2,3,5	1.4,3.2,0.9	4.2,11.3,9.8	13
1dwd	alpha thrombin + hirudin	NAPAP	31	7	664	7	1	0.6	4.7	11
1etr	epsilon thrombin	MQPA	32	6	774	16	2,15,16	0.8,1.3,2.4	5.1,5.5,6.6	11
1fbp	fructose-1,6 biphosphatase ^h	F6P	32	6	593	5	3	1.8	3.9	12
		AMP					(4)	(1.1)	(1.2)	
1gca	galactose binding protein	d-galactose	32	5	575	9	1	0.7	0.8	11
1hew	lysozyme	NAG	13	8	211	1	1	0.7	6.9	5
1hvr	HIV 1 protease ⁱ	XK263	20	10	385	2	1,2	1.2,0.8	2.3,6.3	8
1hyt	thermolysin	BZS	32	6	492	4	1	0.8	2.2	13
1inc	elastase	benzoxazinone	24	9	403	4	4	1.9	5.7	8
1jst	CDK2 - cyclin A complex ^h	ATP	59	7	1326	15	2	1.4	1.5	27
1pbe	p-hydroxybenzoate hydroxylase	FAD	41	10	935	10	1,2,6	1.5,1.0,0.8	7.2,12.6,2.5	16
		PHB					(9)	(1.8)	(1.7)	
1phf	cytochrome p450-cam ^h	C4PI	43	7	723	6	1	0.7	0.9	17
1ppc	trypsin	NAPAP	22	5	304	2	1	1.0	4.8	6
1rbp	retinol binding protein	retinol	19	7	377	4	1,2	0.6,0.4	3.2,5.5	7
1rob	ribonuclease A	cytidylic acid	13	9	236	2	2	0.5	2.4	4
1stp	streptavidin	biotin	12	7	197	2	1	0.4	1.1	3
1ulb	purine nucleoside phosphorylase ⁱ	guanine	30	9	596	3	1	1.3	3.1	10
2er6	endothiapepsin	H256	31	7	487	3	1,2,3	1.9,1.0,0.8	8.7,7.6,1.2	11
2ifb	fatty acid binding protein	palmitic acid	14	6	292	3	1,2	0.4,0.8	1.8,6.6	5
2ipi	beta trypsin	PTI	22	5	305	2	1,2	1.1,2.6	19.4,19.8	7
2pi	triose phosphate isomerase ^h	PGA	25	9	486	5	4	3.4	5.7	8
3aah	methanol dehydrogenase ^h	PQQ	64	7	997	8	4	0.5	3.1	30
3pb	beta trypsin	benzamide	22	6	290	2	1	0.9	0.8	7
4dfr	dihydrofolate reductase ^h	methotrexate	17	8	366	3	1	3.9	8.1	5
4mbn	myoglobin	heme	16	5	297	3	1,2	0.8,0.5	5.4,5.9	5
4phv	HIV 1 protease	VAC	20	7	397	2	1,2	0.7,0.7	2.1,7.1	6
5cna	concanavalin A ^h	MMA	24	6	309	2	(3)	(0.3)	(1.4)	8
7cpa	carboxypeptidase A	FVF	32	6	481	3	2,3	0.6,1.0	6.5,3.1	14

^aDefault PASS parameters used; bound waters removed. Molecular weights do not include hydrogen. Parenthetical entries were obtained in "more" mode (see text). ^bLigand abbreviations: DUMP = 2'-deoxyuridine 5'-monophosphate, NAD = nicotinamide adenine dinucleotide, NAPAP = N=a--(2-naphthyl-sulfonyl-glycyl)-DL-P-amidinophenylalanyl-piperidine, MQPA = (2i,4r)-4-methyl-1-[Nalpa-(irs)-3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl]-L-arginyl]-2-piperidine carboxylic acid, F6P = fructose 6-phosphate, AMP = adenosine monophosphate, NAG = tri-n-acetylchitotriose, BZS = benzylsuccinic acid, ATP = adenosine-5'-triphosphate, FAD = flavin-adenine dinucleotide, PHB = p-hydroxybenzoic acid, C4PI = camphor 4-phenyl imidazole, cytidylic acid = cytidine 2'-monophosphate, PTI = pancreatic trypsin inhibitor, PGA = 2-phosphoglycolic acid, PQQ = pyroloquinoline quinone, VAC = n,n-bis-2(r)-hydroxy-1(s)-indanyl-2,6-(r,r)-diphenylmethyl-4-hydroxy-1,7-heptandiamide, MMA = alpha-methyl-d-mannopyranoside, FVF = bz-phe-val-phe-phe. ^cNumber of active site points (ASPs). ^dRank of ASP(s) lying within 4 Å of the ligand. ^eDistances from binding site hits to the nearest atom in the ligand. ^fDistances from binding site hits to the center of mass of the ligand. ^gCPU Times in seconds on a single Silicon Graphics R10000 processor running at 194 MHz. ^hDimer truncated to a monomer. ⁱNo water in the PDB file. ^jPhosphorylated protein. ^kHeme treated as part of the protein. ^lTetramer truncated to a monomer.

and bound water molecules were ignored. For each PDB complex, Table 3 shows the number of layers of probes PASS computed prior to convergence, the final number of probe spheres, the number of ASPs identified for each protein structure, and the required CPU time. Coordinates of the known ligand(s) are used to define a binding site “hit.” In particular, for each ASP of a particular protein, two quantities are computed: (i) D_{Near} , the distance from the ASP to the nearest ligand atom, and (ii) D_{COM} , the distance from the ASP to the ligand center of mass (COM). Any ASP with $D_{\text{Near}} \leq 4 \text{ \AA}$ is considered a binding site “hit.” The Binding Site Hits column lists the rank order of the ASP(s) that are considered hits, and the values in the D_{Near} and D_{COM} columns correspond to these hits. For instance, the “1hvr” row in Table 3 indicates that both the top ASP and the second-ranked ASP lie near the site in HIV-1 protease known to bind XK263. In particular, the top ASP lies 1.2 \AA from the nearest XK263 atom and 2.3 \AA from the COM, while the second-ranked ASP lies 0.8 \AA from the nearest atom and 6.3 \AA from the COM. Note that ligand size impacts the D_{COM} values, as evidenced by the trypsin-PTI system, which has the largest ligand (a protein) and, correspondingly, the largest D_{COM} values ($\sim 19 \text{ \AA}$).

Table 3 shows that PASS is able to successfully identify the locations of known binding sites in complexed x-ray structures. PASS located the pocket containing a known ligand in all but three of the 32 trials, often finding multiple binding site hits for a given ligand (11 times). In addition, the top-ranking ASP identified by PASS represents a binding site hit in 19 of the 32 trials, and one of the top three ASPs is a hit in 26 trials. These observations indicate that PASS can usually identify the protein cavity to which a ligand will bind with maximal affinity in a matter of seconds. There is a strong, but not

perfect, correlation between ASP rank (i.e. PW) and the volume of the corresponding group of probe spheres. In fact, volume is approximately as predictive of binding sites (results not shown) as ASP rank for the systems in Table 3. However, the calculation of volumes slows PASS noticeably for systems requiring many probe spheres (e.g. 92, 40, and 24 seconds for 1jst, 3aah, and 1etr, respectively).

From a drug design perspective, the analysis presented in Table 3 is somewhat immaterial, since the existence of complexed coordinates implies that at least one binding site location is already known. Intuition suggests that the presence of a ligand in a complex might induce a more pronounced binding site cavity than would be present in an apo-protein structure, thereby biasing a cavity-detection algorithm like PASS to succeed on complexed systems. Thus, the postdiction of binding sites in PDB complexes does not establish the predictive utility of a tool for drug design, where one is lucky to have an apo x-ray structure or reliable homology model.

A more realistic test of PASS as a tool for prediction is to try to locate known binding sites on the structures of proteins that are not complexed with a ligand. We address this predictability issue by using PASS to compute ASPs for the set of apo-protein structures from the PDB that correspond to complexed PDB structures in Table 3. Apo structures were identified for as many of the systems in Table 3 as possible (20), and default PASS parameters were used in all calculations. A few of these PDB correspondences are not identical residue-by-residue because the molecules either were obtained from different sources (1npc/1hyt; 2apr/2er6), had residue additions or deletions at the termini (1swb/1stp; 1hxf/1dwd), or had incomplete or missing residues due to poor electron density (5dfr/4dfr; 1hxf/1dwd). For comparison, the results

displayed in Table 4 are presented in the same order as in Table 3, and corresponding PDB codes are shown. "Known" binding site positions are determined by superposing the native and complexed structures and computing the proximity of the ASPs (from the native PASS calculation) to the known ligand (from the complexed crystal structure). This enables binding site "hits" to be computed as in Table 3, along with the distances D_{Near} and D_{COM} relating the position of the known ligand to the binding site hits. Only backbone atoms {C,O,C $_{\alpha}$,N} were superposed and, in all but a few cases (see Table 4 caption), all residues in the chain were used. To quantify how severely the ligand deforms the protein in the binding site, we computed the RMSD between superposed structures using only residues lying in this region. In particular, we identified both the set {C $_i$ } of residues lying within 4 Å of the ligand in the complex and the set {A $_i$ } of corresponding residues in the superposed apo structure. The RMSD between {C $_i$ } and {A $_i$ } was then computed, using both side chain and backbone atoms for identical amino acids and only the backbone atoms otherwise.

Table 4 shows that PASS can reliably predict binding site locations when only an apo x-ray structure is known. PASS correctly identifies the binding site in 17 of the 21 trials in Table 4. The top-ranked ASP hits the binding site in 12 trials, and one of the top three ASPs is a hit in 16 trials. These observations imply that PASS may be a suitable front-end to virtual high throughput screening and fast docking routines. Furthermore, the similarity of observed hit rates between the apo-protein and complexed systems refutes the hypothesis that the presence of a ligand in the structural data is a crucial determinant of success for a cavity detection algorithm.

Table 4 - PASS Results for PDB Apo-Proteins*

Apo PDB Code	Protein	Complex PDB Code	Probes	ASPs ^b	Binding Site RMSD ^c	Binding Site Hits ^d	D _{near} (Å) ^e	D _{com} (Å) ^f
3tms	thymidylate synthase	1bid	577	4	1.7	1	3.9	6.8
8adh	alcohol dehydrogenase	1cdo ^g	656	3	1.2	1,2	0.2,3.1	5.1,12.0
1hxf	alpha thrombin + hirudin	1dwd	627	8	0.7 ^h	1,4	0.7,1.4	3.7,5.0
2fbp ⁱ	fructose-1,6 biphosphatase	1fbp ^j	564	7	1.3	-	-	(4.8)
						-	-	(2.2)
1gcg	galactose binding protein	1gca	471	3	0.4	1	0.5	1.0
1hel	lysozyme	1hew	219	1	0.7	1	1.0	6.9
1npc	thermolysin	1hyt	455	3	1.7 ^h	1	1.7	2.2
1esa	elastase	1inc	349	1	1.1	-	-	(4.6)
1brq	retinol binding protein	1rbp	401	2	2.2	1	0.9	3.4
8rat	ribonuclease A	1rob	216	2	0.6	1	0.3	1.8
1swb ^k	streptavidin	1stp	199	1	0.7 ^h	1	0.8	2.4
1ula	purine nucleoside phosphorylase	1ulb	637	7	2.6	7	3.9	5.8
2apr	endothiapepsin	2er6	531	5	1.2 ^h	2,5	1.5,0.9	2.6,9.0
1lfb	fatty acid binding protein	2lfb	291	4	0.6	1,2	2.5,0.9	4.6,4.1
3ptn	beta trypsin	3ptb	322	2	0.5	2	0.5	2.6
1ypi ^l	triose phosphate isomerase	2ypi ^l	508	7	2.4	3	2.2	2.0
5dfr	dihydrofolate reductase	4dfr ^l	283	2	1.3 ^h	1	2.3	6.7
3phv ^m	HIV 1 protease ⁿ	4phv	348	1	3.2	-	-	(5.1)
2ctv	concanavalin A	5cna ^o	361	4	1.1	2	0.6	1.0
5cpa ^l	carboxypeptidase A	7cpa ^l	448	3	2.0	1	1.2	4.6

*Default parameters used; bound waters removed. Parenthetical entries were obtained in "more" mode (see text). ^bNumber of active site points (ASPs).

^cAll residues in the proteins were superposed (heavy backbone atoms only), except where noted by superscript n. Binding site RMSDs are computed between all residues that lie within 4 Å of the ligand in the complexed structure and the corresponding residues in the apo structure (heavy atoms only).

Notation: 1abc (10,2) indicates that, for structure 1abc, the binding-site RMSD calculation involved 12 residues, 10 of which included both backbone and sidechain atoms, while 2 included only backbone atoms (since corresponding residues were not of the same type). 3tms (12,0), 8adh (27,11), 1hxf (18,0), 2fbp (28,0), 1gcg (15,0), 1hel (11,0), 1npc (14,0), 1esa (14,0), 1brq (16,0), 8rat (8,0), 1swb (16,0), 1ula (8,0), 2apr (18,5), 1lfb (12,0), 3ptn (11,0), 1ypi (13,0), 5dfr (16,0), 3phv (26,0), 2ctv (9,0), 5cpa (18,0). ^dRank of ASP(s) lying within 4 Å of the superposed ligand. ^eDistances from binding site hits to the nearest atom in the superposed ligand. ^fDistances from binding site hits to the center of mass of the superposed ligand. ^gDimer truncated to a monomer. ^hTetramer truncated to a monomer. ⁱ3phv dimer explicitly created via symmetry operators. ^jZn was considered part of the protein. ^kPASS performed on dimer. ^lResidue superpositions- 1hxf: {A44,F199,E217}; 1npc: {T2,G3,T4,F282,K308,V316} of 1npc with {T2,G3,T4,F281,K307,V315} of 1hyt; 1swb: all residues except {K134,P135} of 1swb (chain A) and {A13,E14,A15} of 1stp; 2apr: {S39,W42,I130} of 2apr with {S36,W39,L128} of 2er6; 5dfr: {A6,N23,V93}.

One additional option available in PASS is the generation of an enhanced set of probes and ASPs by running PASS in “more” mode via the [-more] command-line flag. In “more” mode, the burial count threshold is slightly reduced (by 10), which typically has the effect of enhancing the number of probe spheres by about a factor of two and ASPs by a factor of two or three, at the expense of about 20-30% in cpu time. When the systems in Tables 3 and 4 are analyzed in “more” mode, the binding site is detected in every case, with no ASP hit ranking worse than ninth. Tables 3 and 4 show (in parentheses) the ASP hits obtained in “more” mode for the few binding sites that the default PASS calculation failed to locate. Detailed inspection revealed that several of these default-mode misses contained an accumulation of probe spheres that fell just beneath the threshold defining an ASP. Running PASS in “more” mode is suggested when broad binding sites are anticipated (e.g. protein-protein association).


The work of Mattos and Ringe [1, 20] constitutes the experimental analog of PASS and enables the most direct comparison of PASS to experimental data. In particular, Mattos and Ringe have soaked elastase crystals with a variety of small organic solvents and crystallographically determined the corresponding protein structures, including bound solvent molecules. These bound organic probes are meant to map out potential binding hot spots on the protein and suggest favorable ligand moieties. This raises the question of whether their organic probes tend to cluster in regions identified via PASS ASPs, which are likewise meant to identify possible hot spots. To address this, PASS was run on elastase and the resulting ASPs were graphically superimposed with Ringe et al.'s organic probes, along with a set of bound ligands drawn from the PDB. Figure 3 shows these results. Several clusters of organic

probes are observed, most notably a large grouping in the active site (S1 pocket). Although only one organic probe lies within 8Å of the top- or second-ranked ASPs, PASS places an ASP near four of the five largest clusters of probes. The inset to Figure 3 shows that the third-ranked ASP (pale blue) lies in the active site about 5Å above the catalytic triad (whose surface is colored green).

Figure 3 also addresses the question of whether clusters of these experimentally derived organic probes are more predictive of binding sites than PASS ASPs. Superposition of the ligands from nineteen elastase PDB complexes enables this comparison. All but three ligands bind in the S1 region of the known active site. The other three stick solely to an alternate site about 10Å away (near S3'), while four molecules employ both sites. PASS identifies this alternate binding site via the fourth-ranked ASP (white); however, since only one organic probe lies in this region, this site cannot be identified solely on the basis of organic probe clusters. Conversely, there is a cluster of organic probes near the S4 binding pocket, but no ASP is placed there (this region is too close to the ASP in the S1 pocket). Thus, clusters of the organic probes of Ringe et al. and the ASPs of PASS appear comparably predictive of the known binding sites in elastase. It should be noted that the physical nature of the probes employed by PASS and by Ringe et al. are drastically different, so one should not expect identical distributions of binding hot-spots in the two cases. Ringe et al. probe the protein surface with small, often quite polar, molecules, precisely the opposite of PASS ASPs, which can be thought of as large and apolar. ASPs are effectively apolar in that they are identified solely on the basis of cavity size, shape and burial, with no regard for e.g. electrostatics and hydrogen bonding. Moreover, the PASS parameters have been

tuned such that only a cavity of a certain critical size can sustain an ASP. Over the set of systems in Table 3, the smallest regions of buried volume containing an ASP are approximately the size of a benzene ring, while ASP regions that bind a ligand are typically three- to ten-fold larger than that. It is gratifying, however, that the central binding site (S1) is unambiguously identified by both methods.

Figure 3 – Comparison to Crystallographically-Determined Organic Probes



PASS was run in "more" mode using a cross-linked structure of elastase provided by Ringe and Mattos. The resulting ASPs are rendered as large spheres and colored according to probe weight, PW (see scale). Crystallographically determined organic probes (acetonitrile, dimethylformamide, acetone, ethanol, isopropanol, hexenediol) are displayed as solid yellow sticks. Although only one organic probe lies within 8Å of the top- or second-ranked ASP, four of the five largest clusters of organic probes lie in a region identified as a potential binding site by PASS. Every E.C.3.4.21.36 elastase complex in the PDB (19 structures, 20 ligands: 1bma, 1btu, 1eai, 1eas, 1eat, 1eau, 1ela, 1elb, 1elc, 1eld, 1ele, 1elf, 1elg, 1esb, 1fle, 1inc, 1jim, 1nes, 9est) was superposed onto the cross-linked elastase structure, and the resulting ligand overlays are shown as orange, blue, and magenta sticks (except for two protein-bound structures, 1eai and 1fle). The inset shows a top view of the protein surface at the active site, with the portion of the surface defined by the catalytic triad colored green. The third-ranked ASP (pale blue) is centrally located in the active site (S1 region), while the fourth-ranked ASP (white) identifies an alternate binding site about 10Å away (S3' region). Only 4 ligands (two of which are proteins) bind to both sites (colored blue). Thirteen of the twenty ligands (colored orange) bind in the S1 pocket but not in the alternate site. The other three ligands (1elf, 1elg, 1nes; colored magenta) bind only to the alternate site. Since only one organic probe lies in this region, probe clusters alone cannot identify this as a potential small molecule binding site. Conversely, a cluster of three organic probes lies in the S4 region, in a pocket that PASS failed to identify because it lies too close (i.e. $R_{ASP}=8$ Å) to the S1 ASP.

Discussion

PASS in a Virtual Screening Environment


The hit rates shown in Table 4 indicate that PASS may serve as a front-end to virtual screening when the binding site is unknown or when alternative binding sites are sought. If the screening tool is fast enough that docking against multiple sites is permissible, then separate screening calculations can be run with the search space centered on the top few PASS ASPs. This strategy should enable identification of the optimal binding mode in most cases, as evidenced by the 71% hit rate to the top two ASPs in Table 4. A number of other screening strategies incorporating PASS are also possible. For instance, a more rigorous procedure could be used to select the “true” binding site from amongst the full set of ASP predictions. Using a docking routine with a more detailed scoring function, the affinity of a ligand for the different ASP regions can be directly compared. Thus, screening a small set of diverse probe molecules or fragments against all the ASPs might enable one to identify the stickiest region of the protein by comparing the scores of the top binders to each ASP region. A large database of ligands could then be computationally screened against this region. Since ASPs are determined using only steric size and shape, the electrostatic (ES) and hydrogen-bonding (HB) character of the ASP sites is arbitrary. One might, thus, search these sites for novel pharmacophores and construct focused combinatorial libraries designed to hit them. Conversely, one could use ES and HB characterization of ASP

regions to select sites most likely to possess affinity for a given class of compounds. Perhaps the most alluring aspect of PASS'S speed is that it (i) permits the expeditious analysis of entire structural databases (e.g. PDB, corporate), and (ii) could provide a suitable bridge between 3D structural modeling and ligand docking in a future drug design project designed to make use of genomic data.

PASS as an Interactive Visualization Tool

A PASS calculation on a moderate-sized protein (~ 30 kD) takes less than twenty seconds on a single Silicon Graphics R10000 processor (Table 3). PASS is, therefore, fast enough to be used interactively in a molecular modeling environment, and has particular utility as a visualization tool for drug design. By default, PASS produces PDB files of probes, ASPs, and ligand(s) (when specified), which can be loaded and rendered separately using any molecular modeling package. Alternately, a full display of the PASS output can be produced in a single step (in supported modeling suites) by executing a PASS visualization script, which loads, renders, and colors the protein, probe spheres, ASPs, and ligand(s). ASP coloring denotes probe weight (PW), while the probe spheres can be colored according to either (i) burial count (BC), (ii) group identity (optionally invoked via [-group]), or (iii) the layer of accretion in which each was identified. Color values (0-50) are encoded onto the B-factor column of the output PDB files containing the probes and ASPs. In runs for which the probes are smoothed and grouped, an integer specifying the group membership of each probe sphere is encoded onto the occupancy column of the probe PDB file. Figure 4 shows a

Figure 4 - PASS Visualization of RNase A




RNase A (1rob) is shown in green and is rendered as a tube for clarity, while the cytidylic acid ligand is rendered in white sticks and is barely visible. The final probe spheres, which have been smoothed, are represented by small spheres and colored according to burial count. Active site points (ASPs) are rendered as larger spheres and colored by probe weight. The second-ranked ASP lies in the binding site.

standard PASS visualization in InsightII® for RNase A (1rob), which is rendered as a tube for clarity. The probes are rendered as small spheres and colored according to BC, while the two ASPs are rendered as larger spheres and colored by PW. The ligand, cytidylic acid, is shown in white and is mostly occluded by probes and the second-ranked ASP. Because the ligand binds to a long groove in the RNase surface rather than a deep pocket, the ASP lying in the true binding site has a lower PW than the one shown at the right, which lies in a rounder cavity.

One advantage of PASS as a visualization tool is that displaying the ASPs relative to the protein enables immediate identification of regions likely to be of interest in drug design. Since the ASPs are centrally located in cavities, one can use the displayed ASPs and a distance-based criterion to quickly identify the residues modulating binding in these regions. For the modeling suites that support subsetting (e.g. InsightII), the PASS visualization scripts automatically define 6 Å, 8 Å, and 10 Å residue-based subsets around each ASP, which facilitate the coloring and specific display of these regions. Figure 5 shows the 8 Å subset of protein residues around the top-ranked ASP of trypsin (3ptb). The ASP is shown in magenta, while the probe spheres are colored by burial count. The residues involved in benzamidinium binding are captured in this subset; e.g. hydrogen-bond partners are indicated by yellow lines. The probe coloring clearly indicates that the mouth of the binding pocket lies to the right, where the probe spheres have lowest burial counts. Because PASS ASPs are centrally located in cavities, 6-10 Å radial subsetting almost always enables selective visualization of all the residues defining a protein cavity.

Figure 5 - Residues Modulating the Binding of Benzamidinium to Trypsin




The residues lining the binding pocket of trypsin (3ptb) are rendered as sticks and colored according to atom type. They were selected by defining an 8 Å residue-based zone centered on the top-ranked PASS active site point, shown in magenta. The bound benzamidinium is shown in white, while the probe spheres near the pocket are rendered as small spheres and colored according to burial count (BC). The BC color scale runs from blue (high BC) to red (low BC), with muted colors denoting intermediate values. Dashed lines represent hydrogen bonds between benzamidinium and trypsin residues (D189 and G219), with distances measured in Angstroms.

By identifying multiple ASPs, PASS also suggests alternate binding sites in proteins for which a primary site(s) of binding has already been established. The pursuit of alternate binding sites is becoming increasingly prevalent in light of the mounting realization that many proteins have more than one biochemical role [21] and are likely to employ separate binding sites in performing distinct biochemical tasks. In addition, many enzymes have allosteric binding sites that effect catalytic activity or substrate binding via the induction of conformational changes upon cofactor binding [22]. PASS can suggest the locations of such sites. Finally, the disruption of protein-protein interactions forms the basis of many drug design efforts, and PASS can be used to identify interfacial pockets that may be suitable targets for drug binding. In particular, interfaces may be identified by using probe spheres to compute a difference map between the bound and unbound forms. This approach can be extended to quickly identify and visualize packing contacts in protein crystals or multimeric forms.

PASS also facilitates the visualization of buried volumes in a protein in that the space occupied by the manifold of probe spheres represents this volume, which can be viewed and manipulated as a solid object by rendering the probes in a space-filling model. Mesh or solid representations of various surfaces (molecular, van der Waals, Connolly) are often used to visualize the shape complementarity of a protein surface for putative ligands or functional groups. Often these surfaces are colored according to some other receptor-based property, such as electrostatics, hydrogen bond propensity, or surface curvature. The idea is that a modeler can use this sort of display to look for likely ligand hot-spots on the protein by visually searching the surface for voluminous invaginations that are colored to indicate favorable complementarity in, say,

electrostatic potential. In reality, ligands only bind to regions possessing enough buried volume to significantly accommodate them. Hence, buried volume is a quantity of central importance in drug design, and the development of methods for informatively displaying such regions should be accorded due attention. Surface representations fail to capture buried volumes directly in that the user is left to infer the buried volume from void space, much of which is obscured from view by the surface. Likewise, colored surface quantities are of most interest near deep invaginations, precisely where the surface is most difficult to see. Unfortunately, user expertise is typically required to overcome such difficulties. PASS takes a more direct approach by filling the buried volumes with a set of unbonded atoms that represent the ASPs and probe spheres. This enables both the size and shape of the buried volumes to be viewed directly, either with or without the protein, using any molecular visualization tool. Rendering the buried volumes as solid allows the user to eyeball the fit of certain ligands and groups to potential hot-spot regions. Figure 6 shows the region of buried volume (orange) lying in the binding cavity of retinol binding protein (1rbp), along with the bound retinol (white), some surrounding residues, and the top- and third-ranked ASPs (in magenta), on the left and right, respectively. Information equivalent to what is color-coded onto protein surface displays can, in principle, be captured by property-based coloring of probe spheres. For instance, the user could perform a finite-difference Poisson-Boltzmann calculation and color the probe spheres according to electrostatic potential, ϕ_{es} . Directly displaying ϕ_{es} in the region of interest, rather than having to infer it from ϕ_{es} at the protein surface, provides a more meaningful view of electrostatics than a surface

Figure 6 - Buried Volume in the Binding Pocket of Retinol Binding Protein



This view of the buried volume inscribing the binding pocket of retinol binding protein (1rbp) was obtained by rendering PASS probe spheres at 1.8 Å radius and coloring them orange. The probes were rendered with slight transparency in order to show the bound ligand (retinol) in white. The top- and third-ranked ASPs, shown in magenta, appear on the left and right, respectively. Protein residues lying within 8 Å of the two ASPs are displayed in ball-and-stick style and colored according to atom type.

representation. Favorable hydrogen-bond donor and acceptor positions can likewise be more meaningfully defined within the manifold of probe spheres than on a protein surface. Interaction-based coloring schemes are not presently automated within PASS, however.

Comparative Study

Many procedures for characterizing and visualizing protein cavities have been presented in the past and, while all differ substantially from PASS, comparative study serves to highlight some of PASS'S strengths and weaknesses. First, almost all prior methods identify cavity regions using some type of regular grid [2, 5, 6, 8-11, 23-26]. A grid simply provides the coordinates of points lying in cavities, which are then used in some fashion to identify boundaries with the protein and, for all but internal voids, with empty space. One disadvantage of using a grid is that its storage consumes memory unnecessarily. Likewise, uncertainties arise relating to the possible dependence of results upon grid spacing or positioning. Orientational dependence was indeed found in the program POCKET [9, 24]. The advantage of implementing a grid is purely algorithmic, as there is no physical reason to use regular geometry when it is well known that protein packing and protein surfaces are extremely irregular [27], if not fractal [28]. The PASS algorithm captures this irregularity by using geometry to project outward from the known atomic coordinates in order to inscribe cavity regions. Although this sort of protein-based approach has been taken by other groups [7, 8, 29, 30], the geometry employed in these studies differ significantly from PASS. Every point in a protein cavity may be thought to represent a sphere that lies exactly tangential to the protein surface. The radius of this sphere is the distance of closest approach, and

the sphere generally touches the protein at one, two, or three points (i.e. atoms). Several authors have used this correspondence (in reverse) to define points lying in cavity regions by specifying a set of probe spheres and using geometry (one-, two-, and/or three-point) to project outward from the protein atoms into the cavity region. For instance, cavity points have been obtained by placing tangential spheres midway between atoms [8, 30] and by rolling a probe sphere over the set of atomic spheres representing the protein [7, 10]. The resulting probe coordinates usually correspond to one or two points of tangency with the protein. However, the sterically optimal packing of a spherical probe against the protein has the probe lying tangent to exactly three atoms, just as a marble that is dropped onto a pile of other marbles will come to rest touching exactly three. Unlike any previous method, PASS uses only three-point geometry to obtain points lying in cavity regions. Consequently, the shape of the rendered manifold of PASS probes represents maximally favorable sterics. One might expect that positioning the probe spheres using only three-point geometry would give rise to a spotty distribution of probes and poorly-shaped buried volume. Practical experience has shown, however, that PASS produces smooth well-shaped buried volume manifolds (e.g. Figure 6), and that using only three-point geometry helps minimize the number of points required to fill protein cavities.

The most ambiguous aspect of cavity characterization lies in deciding where to place the boundary between the pocket and free space; i.e. determining “sea-level” [8]. Several studies appearing in the literature [5, 6, 10] operate by filling fully-enclosed volumes (e.g. “flood fill”) and, thus, require an artificial means of closing-off the mouths of cavities in order to define sea-level. With many other methods [8, 9, 23, 24], the definition of sea-level arises as a biproduct of the algorithm itself and has no physical significance. The work of Kuntz et al. [7] is closest in spirit to the present study with

regard to sea-level definition. Their method uses the Connolly surface as a substrate for sphere growth and rejects spheres based upon two criteria: (1) an angular condition, which essentially selects concave regions over flat or convex ones, and (2) a 5Å upper bound on radial sphere growth. Their radial constraint is expected to generate sea-level boundaries similar to those found with PASS. Unlike any other method of cavity detection, however, PASS explicitly defines sea-level according to a quantity of known physical significance, solvent accessibility, as quantified by burial counts (BC).

Computational speed and ease of use are also important criteria for comparison and, in these categories, PASS rates favorably with all published methods. Although reliable speed comparison is difficult since few studies report CPU times [2, 8, 10, 26, 30] and others report times on old processors [5, 7, 11, 29], the fastest CPU times reported in the literature belong to the LIGSITE program of Hendlich et al. [24], which can analyze a moderate-sized protein (at 0.5 Å grid spacing) in about 15 seconds. This is approximately the same speed demonstrated by PASS; however, the LIGSITE CPU time ramps-up very steeply as the grid spacing is reduced (twelve-fold slower at 0.25 Å), and the authors provide only a cursory investigation of the dependence of their results upon grid scale. PASS also excels in useability in that it requires no startup cost to use because the inputs are simple and the outputs are standard. A few programs in the literature appear to have shared this design perspective [8, 23, 24, 29]. The input to PASS is restricted to a PDB file(s) specifying the protein(s) coordinates plus a few optional command-line flags that can be used to control more detailed behavior. PASS produces versatile output in the form of standard PDB files, which allows the user to immediately view the results using whatever modeling tool is already familiar.

Physical Underpinnings

Although the roots of the PASS algorithm are geometrical, not statistical mechanical, it is useful in light of PASS'S success in identifying known binding sites to examine *a posteriori* which physical interactions (if any) are mimicked in PASS. PASS takes the philosophy that the task of binding site prediction is to identify regions of space along the protein where an arbitrary ligand might tightly bind. A physically well-designed algorithm should incorporate as many contributions to binding affinity as possible without sacrificing applicability over a wide range of ligands. Binding affinity is dictated by the free energy change induced by the binding process, ΔG_{bind} , which is known to have numerous contributions, both enthalpic and entropic. While there is disagreement regarding some factors [31-33], sterics, electrostatics, hydrogen-bonding, and solvation are known to be major players [34-38]. Of course, the fine details of ligand size, shape, flexibility, hydrogen-bonding propensity, and polar character are crucial determinants of ΔG_{bind} ; however, the observation that proteins usually bind ligands strongly at only a few sites suggests that one might be able to use coarse details of ligand character (e.g. size) to identify these few binding sites. Thus, PASS must make its predictions using only binding affinity contributions that depend upon coarse ligand character. Two important contributions to ΔG_{bind} fit this description: solvation and sterics. Ligand binding is always favored entropically by the desolvation of molecular moieties, regardless of polarity [39]. This is because the hydration of any atomic group causes net ordering in the first few solvation shells of surrounding water. The PASS algorithm mimics this desolvation effect via the rejection of probe spheres based upon burial count. Likewise, the formation of steric (i.e. enthalpic van der Waals)

contacts between ligand and protein is generally favorable, regardless of the ligand. Although the steric contribution to ΔG_{bind} depends upon detailed molecular shape, the hardness of the steric interaction precludes any ligand from binding tightly to the protein without adopting a configuration consistent with the size and shape of the buried volume. PASS includes sterics by imposing an implicit size and shape criterion upon which regions of buried volume can be identified as active site points (ASPs). In particular, a region of buried volume that is either too small or too narrow to contain even a small ligand without steric clash will never contain an ASP because too few probe spheres will lie in the region for any one to have a large enough probe weight to be selected as an ASP. The PASS parameters (esp. R_o and PW_{min}) have been empirically tuned to make this distinction reliably.

Similar arguments cannot be made regarding the electrostatic interaction, for instance, which may contribute either attractively or repulsively to ΔG_{bind} , depending upon ligand charge and polarity. Several other programs in the literature, however, implement energetics in an effort to use other factors (e.g. hydrophobicity, electrostatics) to help identify and rank potential binding site cavities [2, 5, 26]. Most notably, Ruppert et al. present the most impressive results in the literature with regard to accuracy in locating binding sites [2]. Their method uses an in-house empirical forcefield to dock three different types of probes (steric, H-bond donor, H-bond acceptor) against the protein binding site. This maps out a set of favorable “probe” positions and permits the identification of “sticky spots” on the protein, which are used as central points to carve-out individual pockets. Although they provide no CPU times, their algorithm requires significant docking and, thus, is probably considerably slower than PASS or LIGSITE. They apply this method to the prediction of binding sites in a

set of 11 PDB complexes and find that their top-ranked pocket contains the ligand in every case. Nine of these eleven cases, however, are included in the PASS test set (Table 3), and strikingly similar results are obtained with PASS. The top-ranked ASP is a binding site hit in eight of the nine overlapping trials, and the second ASP is a hit in the other case. Although factors such as electrostatics and hydrogen-bonding certainly contribute to the affinity of a ligand for a particular cavity, the perspective taken in PASS is that only the most ligand-independent contributions to binding (i.e. size, shape, and burial extent of cavities) should contribute to binding site prediction. Energetic factors that strongly modulate specificity should be addressed case-by-case, either manually by the user or via downstream software (e.g. docking). Thus, the PASS ASP regions are completely inclusive with regard to electrostatic and hydrogen-bonding character, with the intention that each will be reinvestigated individually in light of a particular application or desired complementarity. PASS'S success in predicting binding sites without electrostatics and hydrogen-bonding constitutes a remarkable restatement of the importance of solvation and sterics in binding.

Conclusions

PASS is a simple cavity detection tool that has utility in both virtual screening and interactive molecular modeling environments. PASS was shown to reliably predict the locations of known binding sites using a set of 20 apo-protein x-ray structures from the PDB, thereby establishing its utility as a front-end to fast docking and virtual screening. Furthermore, for the price of a thirty-second investment, PASS provides the user a meaningful view of the buried volumes in a protein, suggests alternate binding

sites, and simplifies detailed visualization of potential binding hot-spots. PASS is freely available in unix executable form (SGI Irix, SunOS, Linux) to all users via the Protein Data Bank web site under "PDB-related Software" (<http://www.pdb.bnl.gov/pdb-docs/software.html>).

Acknowledgements

The authors thank Carla Mattos and Dagmar Ringe for providing their elastase structure with bound organic probes and Zelda Wasserman for critical review of the manuscript. GPB thanks the DuPont Pharmaceuticals Company for postdoctoral support during this work.

Appendix A - Three-Point Sphere Geometry

The sphere placement algorithm in PASS hinges upon solution of the following geometry problem. Given three “base” spheres (i, j, and k) of known positions (\mathbf{R}_i , \mathbf{R}_j , \mathbf{R}_k) and radii (σ_i , σ_j , and σ_k), at what two positions (\mathbf{R}_p) can a “probe” sphere of radius σ_p be placed so as to be exactly tangential to all three base spheres? We seek the general solution, in which none of the radii are necessarily equal and the coordinates of the base spheres are unconstrained. Figure A1 illustrates the situation: sphere perimeters are outlined, base sphere centers are labelled “i”, “j”, “k”, the “base plane” (i-j-k) is shaded, the probe sphere is shaded and labelled “p”, and vectors are denoted with uppercase lettering while points and distances are in lowercase. The global origin coordinates is labelled “O”, while a local frame is defined by unit vectors $\{\mathbf{x}', \mathbf{y}', \mathbf{z}'\}$. There are, in general, two solutions for \mathbf{R}_p , one on either side of the base plane. However, one must first impose several conditions to ensure the existence of a solution. If any pair $\{i,j\}$ of base spheres are too far apart, the probe will be unable to bridge the gap, so one must first ensure that $|\mathbf{R}_j - \mathbf{R}_i| \leq \sigma_i + \sigma_j + 2\sigma_p$, and likewise for pairs $\{i,k\}$ and $\{j,k\}$. One must also make sure that no base sphere lies entirely within the volume occupied by the other two. With these conditions satisfied, the coordinates \mathbf{R}_p of the two valid probe sphere positions may be written

$$\mathbf{R}_p = \mathbf{R}_b \pm h\mathbf{z}', \quad (\text{A.1})$$

where h is the height of the probe above the base plane, and \mathbf{z}' is a unit normal to this plane. To be precise, the local coordinate frame $\{\mathbf{x}', \mathbf{y}', \mathbf{z}'\}$ is right-handed, with \mathbf{x}'

lying along $\mathbf{R}_j - \mathbf{R}_i$ and \mathbf{z}' pointing out of the base plane in the direction of $\mathbf{x}' \times (\mathbf{R}_k - \mathbf{R}_i)$.

The right triangle i-b-p gives the height

$$h = \sqrt{(\sigma_i + \sigma_p)^2 - |\mathbf{R}_b - \mathbf{R}_i|^2} . \quad (\text{A.2})$$

The vector \mathbf{R}_b from O to the point of projection of the probe onto the base plane, b, can be written vectorially as

$$\mathbf{R}_b = \mathbf{R}_i + (\mathbf{T}_{ij} - \mathbf{R}_i) + \mathbf{U} , \quad (\text{A.3})$$

which leaves \mathbf{T}_{ij} and \mathbf{U} undetermined. In general, point b need not lie on the interior of triangle i-j-k, as drawn, but the equations are the same in either case. \mathbf{U} can be eliminated from Eqn. (A.3) by observing that

$$\mathbf{U} \cdot (\mathbf{T}_{ik} - \mathbf{R}_i) = \mathbf{V} \cdot (\mathbf{T}_{ik} - \mathbf{R}_i) , \quad (\text{A.4})$$

where $\mathbf{V} \equiv \mathbf{T}_{ik} - \mathbf{T}_{ij}$, and \mathbf{U} points in the direction of \mathbf{y}' . Solving Eqn. (A.4) for \mathbf{U} yields

$$\mathbf{U} = \frac{(\mathbf{T}_{ik} - \mathbf{T}_{ij}) \cdot (\mathbf{T}_{ik} - \mathbf{R}_i)}{(\mathbf{T}_{ik} - \mathbf{R}_i) \cdot \mathbf{y}'} \mathbf{y}' . \quad (\text{A.5})$$

The remaining vectors $\{\mathbf{T}_{ij}, \mathbf{T}_{ik}, \mathbf{T}_{jk}\}$, which run from O to points $\{t_{ij}, t_{ik}, t_{jk}\}$, are found by considering the triangles formed by two base spheres and the probe sphere. For instance, the triangle i-j-p comprises two right triangles, i- t_{ij} -p and j- t_{ij} -p. Applying the Pythagorean theorem to each enables determination of the distance from i to t_{ij} via a quadratic equation, which yields the desired vector


$$\mathbf{T}_{ij} = \frac{1}{2}(\mathbf{R}_i + \mathbf{R}_j) + \frac{(\sigma_i + \sigma_p)^2 - (\sigma_j + \sigma_p)^2}{2|\mathbf{R}_j - \mathbf{R}_i|^2}(\mathbf{R}_j - \mathbf{R}_i) . \quad (\text{A.6})$$

Swapping indices in Eqn. A.6 gives analogous equations for \mathbf{T}_{ik} and \mathbf{T}_{jk} . The normal vector, \mathbf{n} , to the plane of tangency (α - β - γ) may also be of interest:

$$\mathbf{n} = C \cdot [\sigma_{kp}^+ \mathbf{r}_i \times \mathbf{r}_j + \sigma_{ip}^+ \mathbf{r}_j \times \mathbf{r}_k + \sigma_{jp}^+ \mathbf{r}_k \times \mathbf{r}_i + (\sigma_{kj}^- \mathbf{r}_i + \sigma_{ik}^- \mathbf{r}_j + \sigma_{ji}^- \mathbf{r}_k) \times \mathbf{r}_p] , \quad (\text{A.7})$$

where $\sigma_{ab}^{\pm} \equiv \sigma_b \pm \sigma_a$, $C \equiv \sigma_p / \sigma_{ip}^+ \sigma_{jp}^+ \sigma_{kp}^+$, and \mathbf{n} is not of unit magnitude.

Figure A1 - Sphere Geometry



References

- 1 Ringe, D., *Cur. Op. Struct. Biol.*, 5 (1995) 825.
- 2 Ruppert, J., Welch, W. and Jain, A.N., *Prot. Sci.*, 6 (1997) 524.
- 3 Connolly, M. L., *J. Appl. Crystallogr.*, 16 (1983) 548.
- 4 Nicholls, A., Bharadwaj, R. and Honig, B., *Biophys. J.*, 64 (1993) A166.
- 5 Ho, C. M. W. and Marshall, G.R., *J. Comput.-Aided Mol. Design*, 4 (1990) 337.
- 6 Kleywegt, G. J. and Jones, T.A., *Acta Cryst.*, D50 (1994) 178.
- 7 Kuntz, I. D., Blaney, J.M., Oatley, S.J., Langridge and R., Ferrin, T.E., *J. Mol. Biol.*, 161 (1982) 269.
- 8 Laskowski, R. A., *J. Mol. Graphics*, 13 (1995) 323.
- 9 Levitt, D. G. and Banaszak, L.J., *J. Mol. Graphics*, 10 (1992) 229.
- 10 Masuya, M. and Doi, J., *J. Mol. Graphics*, 13 (1995) 331.
- 11 Voorintholt, R., Kusters, M.T., Vegter, G., Vriend, G. and Hol, W.G.J., *J. Mol. Graphics*, 7 (1989) 243.
- 12 Stouten, P. F. W., Froemmel, C., Nakamura, H. and Sander, C., *Molecular Sim.*, 10 (1993) 97.
- 13 Cerius2 v3.8, Molecular Simulations Inc., San Diego, 1998.
- 14 InsightII v97.2, Molecular Simulations Inc., San Diego, 1998.
- 15 MOE v1997.09, Chemical Computing Group Inc., Montreal, 1997.
- 16 Quanta v97.1003, Molecular Simulations Inc., San Diego, 1997.
- 17 RasMol v2.6, Roger Sayle, Hertfordshire U.K., 1997.
- 18 Sybyl v6.5, Tripos Inc., St. Louis, 1998.
- 19 Kurita, T., *Pattern Recognition*, 24 (1991) 205.
- 20 Mattos, C., and Ringe, D., *Nature Biotechnology*, 14 (1996) 595.
- 21 Ringe, D., *Personal Communication*, 1998.
- 22 Hurley, J. H., *Cur. Op. Struct. Biol.*, 6 (1998) 770.
- 23 Delany, J. S., *J. Mol. Graphics*, 10 (1992) 174.
- 24 Hendlich, M., Rippmann, F. and Barnickel, G., *J. Mol. Graphics and Modelling*, 15 (1997) 359.

- 25 Kisljuk, O. S., Kachalova, G.S. and Lanina, N.P., J. Mol. Graphics, 12 (1994) 305.
- 26 Young, L., Jernigan, R.L. and Covell, D.G., Protein Science, 3 (1994) 717.
- 27 Kurochkina, N. and Privalov, G., Prot. Sci., 7 (1998) 897.
- 28 Lewis, M. and Rees, D.C., Science, 230 (1985) 1163.
- 29 Del Carpio, C. A., Takasashi, Y. and Sasaki, S., J. Mol. Graphics, 11 (1993) 23.
- 30 Williams, M. A., Goodfellow, J.M. and Thornton, J.M., Prot. Sci., 3 (1994) 1224.
- 31 Brady, G. P. and Sharp, K.A., Cur. Op. Struct. Biol., 7 (1997) 215.
- 32 Holtzer, A., Biopolymers, 35 (1995) 595.
- 33 Murphy, K. P., Xie, D., Thompson, K.S., Amzel, L.M. and Freire, E., Protein Struct. Funct. Gen., 18 (1994) 63.
- 34 Ajay, Murcko, M.A. and Stouten, P.F.W., In Charifson, P. S. (ed.) Practical Application of Computer-Aided Drug Design , Marcel Dekker, New York, 1997, pp. 355.
- 35 Brady, G. P. and Sharp, K.A., Biophys. J., 72 (1997) 913.
- 36 Gilson, M. K., Given, J.A., Bush, B.L. and McCammon, J.A., Biophys. J., 72 (1997) 1047.
- 37 Kauzmann, W., Adv. Prot. Chem., 14 (1959), 1.
- 38 Makhatadze, G. I. and Privalov, P.L., Adv. Prot. Chem., 47 (1995) 307.
- 39 Madan, B. and Sharp, K.A., J. Phys. Chem., 100 (1996) 7713.
- 40 Bondi, A., J. Phys. Chem., 68 (1964) 441.